Brian O’Callaghan – CEO, ObsEva
Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into…
In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and…
Dr Nicolas Fischer introduces Light Chain Bioscience, a Swiss biotech company focusing on the discovery and development of bispecific antibodies using proprietary technology. Fischer also outlines the competitiveness of Light…
Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva…
After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her own research lab, Professor Susan M.…
Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in…
Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer…
Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in…
Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent…
Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised…
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology…
See our Cookie Privacy Policy Here
